1. R&D Centers
  2. R&D Strength
  3. Clinical Research
  4. Pipeline

Using PSO (Proven, Short-cut, Oversea) R&D strategy, Zelgen selects certain kinds of drugs as our prior targets such as those are proven in Europe or the United States, but are addressing unmet medical needs in China. After accurate and efficient optimizations by using Zelgen's unique platform, the compounds are quickly advanced into clinical trials, overcome production technology bottleneck, and get to the market in a leading position countrywide.

Zelgen's pipeline is mainly covering three disease areas, cancer, hematologic diseases and surgery bleeding. These diseases include liver cancer, renel cancer, colon rectal cancer, lung cancer, esophageal cancer, thyroid cancer, gastric cancer,nasopharyngeal cancer, acute myeloid leukemia, myelofibrosis, MDS, hemophilia, surgery bleeding, etc. Recently, Zelgen also directed the R&D efforts to the treatment of chronic and benign hepatic diseases and autoimmune disorders to expands the treatment areas.


Drug Pipeline